Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease
Trypanosoma cruzi trans-sialidase is a potential target for Chagas disease chemotherapy. From the specific need of T. cruzi to obtain sialic acid through trans-sialidase-mediated transfers from host sources and the lack of alternative to this for the parasite, a good case can be made for T. cruzi tr...
Gespeichert in:
| Veröffentlicht in: | Drug discovery today 2008-02, Vol.13 (3), p.110-117 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 117 |
|---|---|
| container_issue | 3 |
| container_start_page | 110 |
| container_title | Drug discovery today |
| container_volume | 13 |
| creator | Neres, João Bryce, Richard A. Douglas, Kenneth T. |
| description | Trypanosoma cruzi trans-sialidase is a potential target for Chagas disease chemotherapy. From the specific need of
T. cruzi to obtain sialic acid through
trans-sialidase-mediated transfers from host sources and the lack of alternative to this for the parasite, a good case can be made for
T. cruzi trans-sialidase to serve as a potential drug target against Chagas disease. This review deals with both the particular aspects relevant to
T. cruzi trans-sialidase as a target and generalises the situation for drug design in its broader aspects on the basis of some special problems in terms of rational drug design that
T. cruzi trans-sialidase raises, particularly those of multiple gene copies and active site plasticity. |
| doi_str_mv | 10.1016/j.drudis.2007.12.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70289107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644607005247</els_id><sourcerecordid>20884472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-9b28933104d11642353590e89d417009e140be6cae81086293bf4917db4810b33</originalsourceid><addsrcrecordid>eNqFkF2r1DAQhoMong_9ByK50bvWmSRtEy-Ew6JH4YAgCt6FNJmuWbrtmrTC_nuz7Ip3epVh8sybycPYC4QaAds3uzqkNcRcC4CuRlEDqEfsGnWnq0ZL8bjUsjFVq1R7xW5y3gGgME37lF2hFl1jQF-z71_cEufJjbykbXmgHLcTjxM_uORyXOZx3h7f8iW5KVc5ujEGl4m7zB33pyovazjyYU5888NtS7-sROXiGXsyuDHT88t5y759eP9187F6-Hz_aXP3UHklcKlML7SREkEFxFYJ2ZSdgbQJCjsAQ6igp9Y70gi6FUb2gzLYhV6VRi_lLXt9zj2k-edKebH7mD2No5toXrPtoDyA0P0XFKC1Up0ooDqDPs05JxrsIcW9S0eLYE_q7c6e1duTeovCFvVl7OUlf-33FP4OXVwX4NUFcNm7cShKfcn4w5Us3Up1-tG7M0dF269IyWYfafIUYiK_2DDHf2_yG8G2oeY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20884472</pqid></control><display><type>article</type><title>Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Neres, João ; Bryce, Richard A. ; Douglas, Kenneth T.</creator><creatorcontrib>Neres, João ; Bryce, Richard A. ; Douglas, Kenneth T.</creatorcontrib><description>Trypanosoma cruzi trans-sialidase is a potential target for Chagas disease chemotherapy. From the specific need of
T. cruzi to obtain sialic acid through
trans-sialidase-mediated transfers from host sources and the lack of alternative to this for the parasite, a good case can be made for
T. cruzi trans-sialidase to serve as a potential drug target against Chagas disease. This review deals with both the particular aspects relevant to
T. cruzi trans-sialidase as a target and generalises the situation for drug design in its broader aspects on the basis of some special problems in terms of rational drug design that
T. cruzi trans-sialidase raises, particularly those of multiple gene copies and active site plasticity.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2007.12.004</identifier><identifier>PMID: 18275908</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antiprotozoal Agents - chemistry ; Antiprotozoal Agents - pharmacology ; Biological and medical sciences ; Chagas Disease - drug therapy ; Chagas Disease - enzymology ; Chagas Disease - pathology ; Drug Design ; Enzyme Inhibitors - chemistry ; Enzyme Inhibitors - pharmacology ; General pharmacology ; Glycoproteins - antagonists & inhibitors ; Glycoproteins - metabolism ; Humans ; Medical sciences ; Molecular Structure ; Neuraminidase - antagonists & inhibitors ; Neuraminidase - metabolism ; Parasitology - methods ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Trypanosoma cruzi ; Trypanosoma cruzi - drug effects ; Trypanosoma cruzi - enzymology</subject><ispartof>Drug discovery today, 2008-02, Vol.13 (3), p.110-117</ispartof><rights>2007 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-9b28933104d11642353590e89d417009e140be6cae81086293bf4917db4810b33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1359644607005247$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20086343$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18275908$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neres, João</creatorcontrib><creatorcontrib>Bryce, Richard A.</creatorcontrib><creatorcontrib>Douglas, Kenneth T.</creatorcontrib><title>Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>Trypanosoma cruzi trans-sialidase is a potential target for Chagas disease chemotherapy. From the specific need of
T. cruzi to obtain sialic acid through
trans-sialidase-mediated transfers from host sources and the lack of alternative to this for the parasite, a good case can be made for
T. cruzi trans-sialidase to serve as a potential drug target against Chagas disease. This review deals with both the particular aspects relevant to
T. cruzi trans-sialidase as a target and generalises the situation for drug design in its broader aspects on the basis of some special problems in terms of rational drug design that
T. cruzi trans-sialidase raises, particularly those of multiple gene copies and active site plasticity.</description><subject>Animals</subject><subject>Antiprotozoal Agents - chemistry</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Chagas Disease - drug therapy</subject><subject>Chagas Disease - enzymology</subject><subject>Chagas Disease - pathology</subject><subject>Drug Design</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>General pharmacology</subject><subject>Glycoproteins - antagonists & inhibitors</subject><subject>Glycoproteins - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Molecular Structure</subject><subject>Neuraminidase - antagonists & inhibitors</subject><subject>Neuraminidase - metabolism</subject><subject>Parasitology - methods</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Trypanosoma cruzi</subject><subject>Trypanosoma cruzi - drug effects</subject><subject>Trypanosoma cruzi - enzymology</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF2r1DAQhoMong_9ByK50bvWmSRtEy-Ew6JH4YAgCt6FNJmuWbrtmrTC_nuz7Ip3epVh8sybycPYC4QaAds3uzqkNcRcC4CuRlEDqEfsGnWnq0ZL8bjUsjFVq1R7xW5y3gGgME37lF2hFl1jQF-z71_cEufJjbykbXmgHLcTjxM_uORyXOZx3h7f8iW5KVc5ujEGl4m7zB33pyovazjyYU5888NtS7-sROXiGXsyuDHT88t5y759eP9187F6-Hz_aXP3UHklcKlML7SREkEFxFYJ2ZSdgbQJCjsAQ6igp9Y70gi6FUb2gzLYhV6VRi_lLXt9zj2k-edKebH7mD2No5toXrPtoDyA0P0XFKC1Up0ooDqDPs05JxrsIcW9S0eLYE_q7c6e1duTeovCFvVl7OUlf-33FP4OXVwX4NUFcNm7cShKfcn4w5Us3Up1-tG7M0dF269IyWYfafIUYiK_2DDHf2_yG8G2oeY</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Neres, João</creator><creator>Bryce, Richard A.</creator><creator>Douglas, Kenneth T.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease</title><author>Neres, João ; Bryce, Richard A. ; Douglas, Kenneth T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-9b28933104d11642353590e89d417009e140be6cae81086293bf4917db4810b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Antiprotozoal Agents - chemistry</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Chagas Disease - drug therapy</topic><topic>Chagas Disease - enzymology</topic><topic>Chagas Disease - pathology</topic><topic>Drug Design</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>General pharmacology</topic><topic>Glycoproteins - antagonists & inhibitors</topic><topic>Glycoproteins - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Molecular Structure</topic><topic>Neuraminidase - antagonists & inhibitors</topic><topic>Neuraminidase - metabolism</topic><topic>Parasitology - methods</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Trypanosoma cruzi</topic><topic>Trypanosoma cruzi - drug effects</topic><topic>Trypanosoma cruzi - enzymology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neres, João</creatorcontrib><creatorcontrib>Bryce, Richard A.</creatorcontrib><creatorcontrib>Douglas, Kenneth T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neres, João</au><au>Bryce, Richard A.</au><au>Douglas, Kenneth T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>13</volume><issue>3</issue><spage>110</spage><epage>117</epage><pages>110-117</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>Trypanosoma cruzi trans-sialidase is a potential target for Chagas disease chemotherapy. From the specific need of
T. cruzi to obtain sialic acid through
trans-sialidase-mediated transfers from host sources and the lack of alternative to this for the parasite, a good case can be made for
T. cruzi trans-sialidase to serve as a potential drug target against Chagas disease. This review deals with both the particular aspects relevant to
T. cruzi trans-sialidase as a target and generalises the situation for drug design in its broader aspects on the basis of some special problems in terms of rational drug design that
T. cruzi trans-sialidase raises, particularly those of multiple gene copies and active site plasticity.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18275908</pmid><doi>10.1016/j.drudis.2007.12.004</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6446 |
| ispartof | Drug discovery today, 2008-02, Vol.13 (3), p.110-117 |
| issn | 1359-6446 1878-5832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70289107 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antiprotozoal Agents - chemistry Antiprotozoal Agents - pharmacology Biological and medical sciences Chagas Disease - drug therapy Chagas Disease - enzymology Chagas Disease - pathology Drug Design Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology General pharmacology Glycoproteins - antagonists & inhibitors Glycoproteins - metabolism Humans Medical sciences Molecular Structure Neuraminidase - antagonists & inhibitors Neuraminidase - metabolism Parasitology - methods Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Trypanosoma cruzi Trypanosoma cruzi - drug effects Trypanosoma cruzi - enzymology |
| title | Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A21%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rational%20drug%20design%20in%20parasitology:%20trans-sialidase%20as%20a%20case%20study%20for%20Chagas%20disease&rft.jtitle=Drug%20discovery%20today&rft.au=Neres,%20Jo%C3%A3o&rft.date=2008-02-01&rft.volume=13&rft.issue=3&rft.spage=110&rft.epage=117&rft.pages=110-117&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2007.12.004&rft_dat=%3Cproquest_cross%3E20884472%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20884472&rft_id=info:pmid/18275908&rft_els_id=S1359644607005247&rfr_iscdi=true |